Quantitatively different red cell/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease.
about
Customizing the genome as therapy for the β-hemoglobinopathiesAlternative donor transplant of benign primary hematologic disordersHematopoietic stem cell transplantation in thalassemia and sickle cell anemiaHematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel.β-globin gene transfer to human bone marrow for sickle cell disease.Hematopoietic Stem Cell Transplantation in an Infant with Immunodeficiency, Centromeric Instability, and Facial Anomaly Syndrome.Therapeutic effects of induced pluripotent stem cells in chimeric mice with β-thalassemia.BAT2 and BAT3 polymorphisms as novel genetic risk factors for rejection after HLA-related SCTAllogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now.Correction of murine hemoglobinopathies by prenatal tolerance induction and postnatal nonmyeloablative allogeneic BM transplants.Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease.Clinical tolerance in allogeneic hematopoietic stem cell transplantation.Allogeneic cellular and autologous stem cell therapy for sickle cell disease: 'whom, when and how'.Reawakening fetal hemoglobin: prospects for new therapies for the β-globin disorders.Mixed chimerism in haemoglobinopathies: from risk of graft rejection to immune tolerance.The role of donor-derived veto cells in nonmyeloablative haploidentical HSCT.The evolution of T-cell depletion in haploidentical stem-cell transplantation.CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD34+ cells.Treosulfan-Based Conditioning Regimen in Sibling and Alternative Donor Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease.Cure for thalassemia major - from allogeneic hematopoietic stem cell transplantation to gene therapy.Gene Therapy for Hemoglobinopathies: Tremendous Successes and Remaining Caveats.Mixed chimerism evolution is associated with T regulatory type 1 (Tr1) cells in a β-thalassemic patient after haploidentical haematopoietic stem cell transplantation.Mathematical modeling of erythrocyte chimerism informs genetic intervention strategies for sickle cell disease.Peripheral red blood cell split chimerism as a consequence of intramedullary selective apoptosis of recipient red blood cells in a case of sickle cell disease.Genome editing and stem cell therapy pave the path for new treatment of sickle-cell disease.Stem cell transplantation after reduced-intensity conditioning for sickle cell disease.In mixed hematopoietic chimerism, the donor red cells win.Split chimerism between nucleated and red blood cells after bone marrow transplantation for haemoglobinopathies.Early CD3+/CD15+ peripheral blood leukocyte chimerism patterns correlate with long-term engraftment in non-malignant hematopoietic SCT.Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies.Allogeneic/Matched Related Transplantation for β-Thalassemia and Sickle Cell Anemia.At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT.Long-term outcome of mixed chimerism after stem cell transplantation for thalassemia major conditioned with busulfan and cyclophosphamide.Relationship between Mixed Donor-Recipient Chimerism and Disease Recurrence after Hematopoietic Cell Transplantation for Sickle Cell Disease.Gene Therapy for Hemoglobinopathies
P2860
Q26751061-AFA7AC0B-0AB0-4D71-9FD0-EC6C87CB5E8FQ26823398-8859625B-5F53-47A5-B987-4A73795B24D0Q26824116-361CC659-AD4F-4555-A55F-2B4E18FECE07Q33558770-64802A32-08F8-4005-957C-1CE8520D5208Q33570348-BF4EB0F9-E116-42FB-BF16-ABA56AC98C8FQ33855687-74B162E9-965A-43D2-8F8E-EC16D298A3D1Q33978886-EB792E9B-2E35-4BD0-8592-3B08C02F02ACQ34465223-AB8130A9-6753-4FAA-BE94-40DE0E667ECBQ35153756-B8629A69-D906-42E7-B065-53E864B9DABDQ36027459-CB85A9C7-BF76-46D7-A549-771C8B565026Q36423553-BD39BBBD-C263-4200-8AF5-9A2AFFC0F1C1Q36596865-2D356259-E44D-49F0-9F3E-97E482577FE7Q37864697-18DBD27C-53EB-4D8D-80DC-685E9312719EQ37969631-CAD1576E-18D8-4960-9DDB-248A55403692Q38035829-9F495AAA-62A0-4DE0-9ACE-EEF79F14D860Q38191280-8BFF4D66-90C5-41FA-AADC-2483E98BCB23Q38514485-0888078C-2B38-4FFA-9A6D-EB6AB436075FQ38673780-AC02262C-811B-422F-B077-EF2382EE0481Q38758476-32A945EE-CA59-4B89-9E3D-8F8D4E48C970Q38908093-367E65EF-F0C7-4999-8832-BD2B0018AA98Q39026510-C6644105-0655-4E1A-9CD6-D518FC493A20Q40798799-A2D84E53-1838-4E15-9871-D4543AC4AE22Q41453938-87D3EE6F-047E-4D35-A336-D2701F19AB99Q41660434-F6E2CD28-1363-42F4-A6B0-E59DFC85C6FFQ42106466-719B46C6-929E-4366-995A-B6A3895AA6E7Q42125870-9CF52D21-AB3B-4BC6-B2EB-433D1546AAA9Q42276884-3F080AFE-6467-4EA7-B819-EE8B571485C2Q42558435-03B9AB2E-F525-4655-AE43-2980B16CB4A5Q42724208-3E14C4D6-9370-47FE-9C0F-3858F4F47B7FQ45722893-B9080898-E247-408A-A1DA-8C7438E8B74AQ45872216-9F10B52E-9BC8-4D33-8930-C49E85CC0308Q47614537-C8FAE1E6-8886-47E4-90BC-1C0AB142AE37Q47693415-B5D62A06-74DA-45FE-A109-23D3CEA77EC7Q50073298-82954461-9529-401C-92F7-9BF106A02959Q50204317-14181939-10D5-44B2-BA4A-C2211D1CB46EQ58795507-6702F7D3-8330-48AB-AAD3-97EBC32EEB7F
P2860
Quantitatively different red cell/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Quantitatively different red c ...... major or sickle cell disease.
@ast
Quantitatively different red c ...... major or sickle cell disease.
@en
Quantitatively different red c ...... major or sickle cell disease.
@nl
type
label
Quantitatively different red c ...... major or sickle cell disease.
@ast
Quantitatively different red c ...... major or sickle cell disease.
@en
Quantitatively different red c ...... major or sickle cell disease.
@nl
prefLabel
Quantitatively different red c ...... major or sickle cell disease.
@ast
Quantitatively different red c ...... major or sickle cell disease.
@en
Quantitatively different red c ...... major or sickle cell disease.
@nl
P2093
P2860
P1433
P1476
Quantitatively different red c ...... major or sickle cell disease.
@en
P2093
Andrea Bontadini
Daniela Fraboni
Francesca Agostini
Francesca Ricci
Giuliana Ferrari
Guido Lucarelli
Javid Gaziev
Lidia De Felice
Manuela Testi
Marco Andreani
P2860
P304
P356
10.3324/HAEMATOL.2010.031013
P577
2010-10-07T00:00:00Z